Pharmacyte Biotech Inc (PMCB)

$0.69 0.00 (-0.69%)
Market Cap 7.41M
Revenue (ttm) 0.00
Net Income (ttm) 30.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 30,200
Avg Vol 245,764
Day's Range N/A - N/A
Shares Out 10.74M
Stochastic %K 39%
Beta 0.33
Analysts Strong Buy
Price Target N/A

Company Profile

PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other soli...

Industry: Biotechnology
Sector: Healthcare
Phone: 917 595 2850
Fax: 917 595 2851
Address:
3960 Howard Hughes Parkway, Suite 500, Las Vegas, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 11 at 5:51 PM
$PMCB RSI: 47.84, MACD: -0.0231 Vol: 0.03, MA20: 0.70, MA50: 0.78 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
topstockalerts
topstockalerts Mar. 10 at 9:24 PM
After Hours Top Gainers PT2 $ORCU $ATOM.X $CODA $BODI $PMCB
0 · Reply
topstockalerts
topstockalerts Mar. 10 at 8:32 PM
After Hours Top Gainers $DOMO $ORCU $ORCX $PMCB $CSTE
0 · Reply
CloudKing
CloudKing Mar. 10 at 12:18 PM
$BNAI $GXAI $OBAI $QCLS $PMCB
0 · Reply
CanadianApe69
CanadianApe69 Mar. 10 at 4:35 AM
$PMCB this will go up. $SPY
0 · Reply
Ron_Burn
Ron_Burn Mar. 6 at 7:00 PM
$PMCB undervalued... might see .92 soon
1 · Reply
CanadianApe69
CanadianApe69 Mar. 6 at 6:46 PM
$ALLR take a look at $PMCB has lots of room to go!
0 · Reply
prismmarketview
prismmarketview Mar. 6 at 5:19 PM
PRISM Mid-Day Movers: Aerospace & Defense and Oil & Gas are Today’s Leaders. Silynxcom (NYSE: $SYNX) is spiking ~54% to $1.59 on surging volume after a fresh ~$400K government tender for its tactical in‑ear comms gear. Trio Petroleum (NYSE: $TPET) tacks on another ~34% to $2.13 as more than 190M shares trade and momentum chases its leveraged bet on volatile crude and a recently cleaned‑up balance sheet. Other Notable Movers: Brand Engagement Network, Inc. ( $BNAI) up 16% PharmaCyte Biotech ( $PMCB) up 13% Owlet, Inc. ( $OWLT) down -36% https://prismmarketview.com/prism-mid-day-movers-aerospace-defense-and-oil-gas-are-todays-leaders/
0 · Reply
CanadianApe69
CanadianApe69 Mar. 6 at 4:18 PM
$TPET out of this popsicle stand and onto $PMCB for a pop.
1 · Reply
J3_16
J3_16 Mar. 6 at 4:14 PM
$PMCB OWNS 84% OF $QCLS
0 · Reply
Latest News on PMCB
PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

Nov 25, 2025, 9:15 AM EST - 3 months ago

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

FEMY

PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications

Sep 2, 2025, 9:20 AM EDT - 6 months ago

PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications

PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing

Aug 20, 2025, 9:15 AM EDT - 7 months ago

PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing

PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors

Aug 18, 2025, 9:15 AM EDT - 7 months ago

PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors

MyMD Pharmaceuticals Secures Strategic Investments

May 21, 2024, 9:00 AM EDT - 1 year ago

MyMD Pharmaceuticals Secures Strategic Investments

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

May 21, 2024, 9:00 AM EDT - 1 year ago

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.

Nov 15, 2023, 8:30 AM EST - 2 years ago

PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.

FEMY

PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology

Oct 31, 2023, 9:15 AM EDT - 2 years ago

PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology

PharmaCyte Biotech Announces Final Results of Tender Offer

Jun 15, 2023, 9:15 AM EDT - 2 years ago

PharmaCyte Biotech Announces Final Results of Tender Offer

PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share

May 11, 2023, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share

PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan

Feb 2, 2023, 9:00 AM EST - 3 years ago

PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan

PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value

Oct 7, 2022, 9:00 AM EDT - 3 years ago

PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value

PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

Aug 15, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

PharmaCyte Biotech Rebukes Iroquois' Commencement of Consent Solicitation

Jul 28, 2022, 12:49 PM EDT - 3 years ago

PharmaCyte Biotech Rebukes Iroquois' Commencement of Consent Solicitation

Iroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc.

Jul 28, 2022, 9:00 AM EDT - 3 years ago

Iroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc.

PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study

Jul 21, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study

PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study

Jul 19, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study

PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022

Jul 11, 2022, 8:30 AM EDT - 3 years ago

PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022

IROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORS

Jul 11, 2022, 6:00 AM EDT - 3 years ago

IROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORS

IROQUOIS CAPITAL ISSUES STATEMENT IN RESPONSE TO RECENT ACTIONS BY THE PHARMACYTE BIOTECH BOARD OF DIRECTORS

Jul 5, 2022, 3:16 PM EDT - 4 years ago

IROQUOIS CAPITAL ISSUES STATEMENT IN RESPONSE TO RECENT ACTIONS BY THE PHARMACYTE BIOTECH BOARD OF DIRECTORS

PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells

Jul 5, 2022, 8:30 AM EDT - 4 years ago

PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells

IROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETING

Jun 23, 2022, 9:00 AM EDT - 4 years ago

IROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETING

PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital's Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value

Jun 15, 2022, 8:30 AM EDT - 4 years ago

PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital's Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value

PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego

Jun 13, 2022, 8:30 AM EDT - 4 years ago

PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego

IROQUOIS CAPITAL DELIVERS OPEN LETTER TO PHARMACYTE BIOTECH BOARD OF DIRECTORS

Jun 9, 2022, 9:00 AM EDT - 4 years ago

IROQUOIS CAPITAL DELIVERS OPEN LETTER TO PHARMACYTE BIOTECH BOARD OF DIRECTORS

PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value

Jun 8, 2022, 8:30 AM EDT - 4 years ago

PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value

PharmaCyte Biotech to Implement $10-Million Share Repurchase Program

Jun 2, 2022, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech to Implement $10-Million Share Repurchase Program

PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites

May 23, 2022, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites

Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors

May 11, 2022, 9:00 AM EDT - 4 years ago

Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors

PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes

Apr 27, 2022, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes

PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements

Apr 19, 2022, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements

PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial

Apr 13, 2022, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial

PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors

Apr 5, 2022, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors

PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate

Mar 22, 2022, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate

PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights

Mar 16, 2022, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights

PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

Feb 22, 2022, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA

Feb 14, 2022, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA

Is This A Good Time To Invest In PharmaCyte?

Jan 7, 2022, 2:59 AM EST - 4 years ago

Is This A Good Time To Invest In PharmaCyte?

PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference

Jan 6, 2022, 9:00 AM EST - 4 years ago

PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference

PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells

Jan 4, 2022, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells

PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study

Dec 28, 2021, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study

PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights

Dec 15, 2021, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights

PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay

Dec 8, 2021, 10:16 AM EST - 4 years ago

PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay

PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study

Nov 30, 2021, 1:05 AM EST - 4 years ago

PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study

PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation

Nov 12, 2021, 9:00 AM EST - 4 years ago

PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation

PharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNA

Sep 27, 2021, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNA

PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests

Sep 21, 2021, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests

Why Are PharmaCyte Shares Moving Higher On Thursday?

Sep 16, 2021, 1:51 PM EDT - 4 years ago

Why Are PharmaCyte Shares Moving Higher On Thursday?

PharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDA

Sep 16, 2021, 9:00 AM EDT - 4 years ago

PharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDA

Why Is PharmaCyte Biotech Stock Moving Higher In Premarket Thursday?

Sep 9, 2021, 8:57 AM EDT - 4 years ago

Why Is PharmaCyte Biotech Stock Moving Higher In Premarket Thursday?

OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 11 at 5:51 PM
$PMCB RSI: 47.84, MACD: -0.0231 Vol: 0.03, MA20: 0.70, MA50: 0.78 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
topstockalerts
topstockalerts Mar. 10 at 9:24 PM
After Hours Top Gainers PT2 $ORCU $ATOM.X $CODA $BODI $PMCB
0 · Reply
topstockalerts
topstockalerts Mar. 10 at 8:32 PM
After Hours Top Gainers $DOMO $ORCU $ORCX $PMCB $CSTE
0 · Reply
CloudKing
CloudKing Mar. 10 at 12:18 PM
$BNAI $GXAI $OBAI $QCLS $PMCB
0 · Reply
CanadianApe69
CanadianApe69 Mar. 10 at 4:35 AM
$PMCB this will go up. $SPY
0 · Reply
Ron_Burn
Ron_Burn Mar. 6 at 7:00 PM
$PMCB undervalued... might see .92 soon
1 · Reply
CanadianApe69
CanadianApe69 Mar. 6 at 6:46 PM
$ALLR take a look at $PMCB has lots of room to go!
0 · Reply
prismmarketview
prismmarketview Mar. 6 at 5:19 PM
PRISM Mid-Day Movers: Aerospace & Defense and Oil & Gas are Today’s Leaders. Silynxcom (NYSE: $SYNX) is spiking ~54% to $1.59 on surging volume after a fresh ~$400K government tender for its tactical in‑ear comms gear. Trio Petroleum (NYSE: $TPET) tacks on another ~34% to $2.13 as more than 190M shares trade and momentum chases its leveraged bet on volatile crude and a recently cleaned‑up balance sheet. Other Notable Movers: Brand Engagement Network, Inc. ( $BNAI) up 16% PharmaCyte Biotech ( $PMCB) up 13% Owlet, Inc. ( $OWLT) down -36% https://prismmarketview.com/prism-mid-day-movers-aerospace-defense-and-oil-gas-are-todays-leaders/
0 · Reply
CanadianApe69
CanadianApe69 Mar. 6 at 4:18 PM
$TPET out of this popsicle stand and onto $PMCB for a pop.
1 · Reply
J3_16
J3_16 Mar. 6 at 4:14 PM
$PMCB OWNS 84% OF $QCLS
0 · Reply
Bill_S_Preston_San_Dimas
Bill_S_Preston_San_Dimas Mar. 6 at 4:07 PM
$QCLS err I’m buying $PMCB here they own a lot of qcls stock
1 · Reply
HenrikTheBandit
HenrikTheBandit Mar. 6 at 3:53 PM
$QCLS is owned by $PMCB invest there before it goes back to $2, easy money.
0 · Reply
HenrikTheBandit
HenrikTheBandit Mar. 6 at 3:35 PM
$QCLS doesnt $PMCB own like 75% of QCLS bit of a delay on the rip there, might play it
0 · Reply
HenrikTheBandit
HenrikTheBandit Mar. 5 at 7:17 PM
$PMCB in
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 4 at 3:21 PM
$PMCB Current Stock Price: $0.69 Contracts to trade: $2.5 PMCB Mar 20 2026 Call Entry: $0.05 Exit: $0.07 ROI: 66% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SinglesOverHomeRun
SinglesOverHomeRun Mar. 2 at 8:55 PM
$PMCB looks like a fraud. Wall Street aint sure though.
0 · Reply
BHWinehouse
BHWinehouse Feb. 20 at 3:42 PM
$QCLS Many moving parts and possibilities. $PMCB could be a key factor in the next move. Remember, this is lurking in the shadows...http://drugapprovalsint.com/isomiosamine/
0 · Reply
Succinct_1
Succinct_1 Feb. 19 at 12:28 AM
$PMCB this one is interesting, they own quite a bit of QCLS. Lots of warrants around $1. 👀
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 18 at 5:33 PM
$PMCB RSI: 28.25, MACD: -0.0500 Vol: 0.10, MA20: 0.80, MA50: 0.85 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Dfastpitchchic5
Dfastpitchchic5 Feb. 11 at 3:09 PM
$PMCB
0 · Reply
_RG1_
_RG1_ Feb. 6 at 9:19 PM
$PMCB Nice Movement
0 · Reply